Dysregulation of COVID-19 related gene expression in the COPD lung

Respiratory Research

Table 1 Demographics of healthy volunteer ex-smoker controls compared with COPD subjects

	HV-ES controls	COPD	P value
Number of patients (total = 51)	20	31
M/F	11/9	25/6	0.06
Age	67.5, IQR = 6.75	70, IQR = 9.5	1.0
FEV1%	100.5, IQR = 11.75	73, IQR = 21	< 0.0001
FEV1/FVC ratio	77.5, IQR = 4.5	58, IQR = 13.5	< 0.0001
Pack-years of smoking	25, IQR = 18.62	44, IQR = 37.5	0.81
BMI, kg/m2	27.69, IQR = 3.61	28.48, IQR = 5.97	1.0
Inhaled corticosteroid use, n (19/68)	0	19	< 0.0001
ACEi use, n (7/68)	3	4	1.0
ARB use, n (6/68)	2	4	1.0
Hypertension, n (16/68)	6	10	1.0
Cardiovascular disease, n (7/68)	0	7	0.03
Diabetes, n (5/68)	1	4	0.63

ARB Angiotensin receptor blockers, ACEi Angiotensin-converting enzyme inhibitor, CVD cardiovascular disease, BMI body mass index, COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in one second, FVC forced vital capacity. HV-ES health volunteer ex-smoker who had stopped smoking for at least 6 months
Data are presented as median and IQR (interquartile range) unless otherwise indicated

ISSN: 1465-993X